Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lichtiger

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
The Mount Sinai Journal of Medicine, New York|October 1, 1990
Cyclosporine therapy in inflammatory bowel disease: open-label experienceS Lichtiger
Inflammatory Bowel Diseases|January 4, 2013
To Use or Not to Use Cyclosporine-A: That is the QuestionS Lichtiger
Digestive Diseases and Sciences|February 1, 1994
Efficacy of cyclosporine in treatment of fistula of Crohn's diseaseD H Present, S Lichtiger
Lancet (London, England)|July 7, 1990
Preliminary report: cyclosporin in treatment of severe active ulcerative colitisS Lichtiger, D H Present
Journal of the American Geriatrics Society|July 1, 1977
Incidence of polypharmacy in a long-term care facilityT Kalchthaler, E Coccaro, S Lichtiger
The Mount Sinai Journal of Medicine, New York|May 1, 1993
Gold-induced colitis: a case report and review of the literatureV Teodorescu, J Bauer, S Lichtiger, et al.
The American Journal of Gastroenterology|October 8, 1997
Cyclosporin for severe ulcerative colitis: a user's guideA Kornbluth, D H Present, S Lichtiger, et al.
The Mount Sinai Journal of Medicine, New York|November 1, 2001
Ulcerative colitis and sarcoidosisN Nilubol, P J Taub, M Venturero, et al.
Alimentary Pharmacology & Therapeutics|November 14, 2008
Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patientsA Swaminath, T Ullman, M Rosen, et al.
Journal of Clinical Gastroenterology|October 1, 1988
Fecal alpha 1-antitrypsin as a measure of Crohn's disease activity. The effect of therapy and anatomical extent of diseaseS Meyers, S Lichtiger, E J Feuer, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
The Mount Sinai Journal of Medicine, New York|October 1, 1990
Cyclosporine therapy in inflammatory bowel disease: open-label experienceS Lichtiger
Inflammatory Bowel Diseases|January 4, 2013
To Use or Not to Use Cyclosporine-A: That is the QuestionS Lichtiger
Digestive Diseases and Sciences|February 1, 1994
Efficacy of cyclosporine in treatment of fistula of Crohn's diseaseD H Present, S Lichtiger
Lancet (London, England)|July 7, 1990
Preliminary report: cyclosporin in treatment of severe active ulcerative colitisS Lichtiger, D H Present
Journal of the American Geriatrics Society|July 1, 1977
Incidence of polypharmacy in a long-term care facilityT Kalchthaler, E Coccaro, S Lichtiger
The Mount Sinai Journal of Medicine, New York|May 1, 1993
Gold-induced colitis: a case report and review of the literatureV Teodorescu, J Bauer, S Lichtiger, et al.
The American Journal of Gastroenterology|October 8, 1997
Cyclosporin for severe ulcerative colitis: a user's guideA Kornbluth, D H Present, S Lichtiger, et al.
The Mount Sinai Journal of Medicine, New York|November 1, 2001
Ulcerative colitis and sarcoidosisN Nilubol, P J Taub, M Venturero, et al.
Alimentary Pharmacology & Therapeutics|November 14, 2008
Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patientsA Swaminath, T Ullman, M Rosen, et al.
Journal of Clinical Gastroenterology|October 1, 1988
Fecal alpha 1-antitrypsin as a measure of Crohn's disease activity. The effect of therapy and anatomical extent of diseaseS Meyers, S Lichtiger, E J Feuer, et al.
Pageof 2